Who are we? Episode #7 Estelle Louet

Through this mini-series of articles, we want to present you the talents of each member of the team.

  • Estelle, can you introduce yourself briefly?

E.L : I am Project Engineer at Op2Lysis. I am also a PhD student, within a collaborative industrial agreement between Op2Lysis and Inserm research unit U1237.

I obtained a Bachelor at the University of Fribourg and a Master in medical biology, with a specialization in neuroscience, at the University of Zurich. I obtained all my degrees in Switzerland, which is the country where I was born

  • Why did you decide to join the Op2Lysis team?

E.L : I was very pleased to join the Op2lysis team. First, because I think that the project is very interesting, both from the scientific and the human perspectives. I am proud to be a part of this project. I always wanted to work for a company that is at the edge of technology and that uses this science to serve the public health care. Additionally, I benefit from the opportunity of strengthening my professional experience and skills beyond my academic training, through this private-public combination.

  • What is the strength of the technology developed by Op2Lysis?

E.L : Our technology is based on perfect knowledge of stroke mechanisms as well as tPA mechanisms of action, which will allow best use of our drug candidate in patients with an intracerebral hemorrhage.

Our product is specifically designed to treat patients with intracerebral hemorrhage easily and with best safety.

  • What is your personal contribution to Op2lysis ?

E.L : As a Project Engineer at Op2Lysis, my responsibility is to conduct the scientific experiments which are required to allow further development of our technology. Therefore, I use daily my scientific skills and technical knowledge, as well as the analytic capacity that I acquired all along my training.

I can participate in some decisions about company communication. I would like to be able to bring new perspectives for the company through my PhD project.

Op2Lysis SAS announced the closing of a first round of fundraising

Discover this announcement in a press release


Op2Lysis is an Innovative Young Company

Op2Lysis has obtained the Innovative Young Company label from the French Ministry of Higher Education and Research. Together with CIFRE contract, this label is the second key support received by Op2Lysis over these last few weeks to strengthen its innovation.

Op2Lysis ranked TOP 10 at Big Booster 2018 and was selected for camps in Boston and Shanghai.

Op2Lysis has been ranked as the 7th best start up (out of the initially 100 companies selected at the beginning of the competition) at the Big Booster Demo Days 2018, in Lyon (France) and is now a member of the 2018 Big Booster Class. This success offers the opportunity to fly to Boston and to Shanghai in the next few months in order to consolidate existing partnerships and to open new opportunities for business with the USA and China.


More information on Big Booster:

The CIFRE Convention, for acceleration of R&D activity

On April 18th, 2018, Op2Lysis has been granted by the Agence Nationale de la Recherche et de la Technologie (ANRT) for its application to CIFRE (Conventions Industrielles de Formation par la REcherche) on the research work to be performed by Estelle LOUET. This positive feedback will reinfoce the R&D capacity of Op2Lysis, while favoring proper training of the research staff. The Convention will favor public-private exchanges between Inserm-Unicaen UMRS1237 research lab, which is based in Caen, and Op2Lysis.

About the CIFRE Convention

For over 30 years, CIFRE (Conventions Industrielles de Formation par la REcherche) provides funding grants to French companies when they hire young PhD students to work on collaborative projects in partnership with public labs. Thesis defense based on this work is to occur within 3 years. CIFRE subventions are entirely funded by the French Ministère de l’Enseignement supérieur, de la Recherche et de l’Innovation. The Agence Nationale de la Recherche et de la Technologie (ANRT) is in charge of implementation.

More information :


Brain Week, March 12-18, 2018

Want to know even more about your brain ?

You should attend the 20th edition of the “brain week” standing from the 12th to the 18th of March. This event is organized every year by the French Society of Neurosciences with the purpose of raising awareness of the largest audience on the role and impact of research in various fields of neurosciences and to better understand our role in this puzzle. To check if there is an event close to your place, please consult (in French):


Stroke symptoms

How to identify stroke symptoms in friends or relatives, including yourself ?

Stroke symptoms are sudden and require immediate management. Therefore, it is critical to know these signs, so that treatment can be quickly initiated
If the following occurs:

  • Sudden trouble in speaking or understanding other people (aphasia) ;
  • Sudden numbness or paralysis of one side of the face ;
  • Sudden numbness or paralysis of one arm or one leg (hemiplégia) ;
  • Sudden loss of sight (often in one signle eye) or double vision ;
  • Sudden loss of balance or body movement coordination ;

Then, call emergency number, to ensure fast management and transfer to a Stroke Unit..

Even if symptoms go away, you should quickly see a doctor.

All you want to know about the name « Op2Lysis »

We are often asked about the meaning of our company name. Here, we tell you more about the history that stands behind this name.

Op2Lysis has to be taken from an English-speaking part. It is a combination of « Op2 » for «Optimize » and « Lysis », meaning literally « optimizing the lysis ».

But, where does the word « lysis » come from ? Is this the name of somebody ? Is this a scientific word ?

The word « lysis » comes from the ancient Greek word « lusis », meaning to untie or to break apart. It is part of words such as analysis, catalysis, electrolysis, pyrolysis, autolysis… Importantly for us, thrombolysis, which is the lysis of a thrombus, is the mechanism of action of our product, O2L-001, to liquefy the blood clot inside of the brain.

Therefore, Op2Lysis is aimed at developing a treatment to favor liquefaction of hematoma or blood clots that result from a hemorrhagic stroke.

Who are we ? Episode #6 Tiffany Le Carff

Through this mini-series of articles, we want to present you the talents of each member of the team

Tiffany Le Carff, can you introduce yourself briefly ?

T.LC : I am in charge of Op2Lysis communication. I obtained a bachelor in Sciences of Information and Communication from University Paris 8, and I then pursued my education to obtain a Master from University Paris 13 in Corporate Communication for Companies, Public Institutions and Associations. This background gave me the opportunity of joining various companies in diverse areas with internal communication and external communication tasks. My responsibility as a Communication Officer is to conceive and implement internal and external communication strategies for the company. The purpose is to ensure a consistent company image. I am in charge of promoting company values, projects and teams. I also provide internal support to the diverse professions of the company.

Why did you join Op2Lysis ?

T.LC : I was very enthusiastic about joining Op2Lysis, for multiple reasons but primarily because of the area of expertise of this company. Everybody knows about somebody around with a stroke, and about relatives who must face a heavy burden when dealing with the severe disability that results from a stroke. Giving a meaning to day-to-day work is very important to me.

In addition, I knew that the company was recently created, providing the opportunity to initiate many communication tasks. I like challenges, and my work at Op2Lysis brings me a chance to face many challenges every day.

What do you bring to Op2Lysis ?

T.LC : The experience that I gained from my previous responsibilities in diverse companies allows me to bring many things to Op2Lysis. My primary role is to develop various communication contents according to the target audience that the company wants to address, while ensuring the consistency of this external communication.

Since I joined Op2Lysis, I have worked extensively on company identity and values, as well as on the graphic chart and messages that allow to promote these values. I think that I have also been able to bring a global vision in communication requirements and to identify further steps of this communication. The purpose is to build a smart communication according to current needs, while anticipating longer term communication strategy.

Who are we ? Episode #5 Jérôme Parcq

Through this mini-series of articles, we want to present you the talents of each member of the team.

Jérôme, can you introduce yourself briefly ?

J.P.: I am engineer in Agronomy, and I then decided to progress to the Doctorate level with a PhD in Neurosciences. Over the last 10 years, I have worked at Inserm Laboratory U1237, University of Caen, with Prof. Denis Vivien in a program dedicated to innovative therapeutic solutions to fight blood clots. I am the inventor of the product developped by op2Lysis. I benefited from complementary trainings at HEC (Challenge +) and INSEAD (Bootcamp Life Sciences), which provided me with the broad and multidisciplinary entrepreneurship skills that I can dedicate to Op2Lysis.

What are your main contrinutions in neurosciences ?

J.P. : During my research activity, I have developed an expertise about the molecule that we are now developing. My research work has led to performing clinical studies in partnership with stroke units in France (the Ophelie study, coordinated by the stroke unit of Lille). Indeed, I have shown that two forms of tissue plasminogen activator (tPA) which looked similar had very different effects on glutamatergic neurotransmission. I have identified the site which potentializes this tPA signal pathway, a work that was the basis of the O2L-001 invention.

What is the main asset of the technology developed by Op2Lysis ?

J.P. : The therapeutic solution that is proposed by Op2Lysis is based on the observation of molecular and cellular mechanisms of tPA in the brain, and is the result of a research program initiated in 2001. This solution, a new generation thrombolytic agent without neurotoxicity, is fully adapted to the intracerebral administration of a treatment for patients with an acute hemorrhagic stroke.

What did you bring to Op2Lysis ?

J.P. : I am the co-founder of Op2Lysis, a project which I initiated in 2010. After meeting with Christophe in 2014, we have been able, together, to accelerate the progress of this program. I am in charge of the operational activities of the company.